Role of rituximab in treatment of patients with primary central nervous system lymphoma: a retrospective analysis of the Czech lymphoma study group registry

Result code in IS VaVaI

<a href="https://www.isvavai.cz/riv?ss=detail&h=RIV%2F00064165%3A_____%2F16%3A10328404" target="_blank" >RIV/00064165:_____/16:10328404 - isvavai.cz</a>

Alternative codes found

RIV/00216224:14110/16:00093410 RIV/00216208:11110/16:10328404 RIV/00216208:11130/16:10328404 RIV/00216208:11150/16:10328404 and 7 more

Result on the web

<a href="http://dx.doi.org/10.3109/10428194.2016.1167203" target="_blank" >http://dx.doi.org/10.3109/10428194.2016.1167203</a>

DOI - Digital Object Identifier

<a href="http://dx.doi.org/10.3109/10428194.2016.1167203" target="_blank" >10.3109/10428194.2016.1167203</a>

Result language

angličtina

Original language name

Role of rituximab in treatment of patients with primary central nervous system lymphoma: a retrospective analysis of the Czech lymphoma study group registry

Original language description

We have investigated whether the addition of rituximab to methotrexate, procarbazine, vincristine, radiotherapy and cytarabine was associated with improved outcome of primary central nervous system lymphomas (PCNSL). Of 164 patients, 49 received rituximab. Median age was 63 years, median Karnofsky performance score (KPS) was 60 and median follow-up of living patients was 59.5 months. 1- and 2-year PFS were 49.7 and 37.9%, 1- and 2-year OS were 57.0 and 453%. Median progression-free survival (PFS), but not overall survival (OS) was significantly better for patients treated with rituximab (22.9 vs. 10.9 months, p = 0.037). In multivariate analysis, age <= 70 years and KPS >= 90 were predictive for PFS and OS, rituximab was an independent prognostic factor for PFS only. In landmark analyses, rituximab was not found beneficial for long-term survivors and no group particularly benefited from rituximab. In conclusion, addition of rituximab was associated with improved PFS, but not OS in this unselected cohort of PCNSL patients.

Czech name

—

Czech description

—

Type

J_x - Unclassified - Peer-reviewed scientific article (Jimp, Jsc and Jost)

CEP classification

FD - Oncology and haematology

OECD FORD branch

—

Project

—

Continuities

V - Vyzkumna aktivita podporovana z jinych verejnych zdroju

Publication year

2016

Confidentiality

S - Úplné a pravdivé údaje o projektu nepodléhají ochraně podle zvláštních právních předpisů

Name of the periodical

Leukemia &amp; Lymphoma

ISSN

1042-8194

e-ISSN

—

Volume of the periodical

57

Issue of the periodical within the volume

12

Country of publishing house

GB - UNITED KINGDOM

Number of pages

7

Pages from-to

2777-2783

UT code for WoS article

000385471000007

EID of the result in the Scopus database

2-s2.0-84963796152